Increased sclerostin levels after further ablation of remnant estrogen by aromatase inhibitors

Sclerostin is a secreted Wnt inhibitor produced almost exclusively by osteocytes, which inhibits bone formation. Aromatase inhibitors (AIs), which reduce the conversion of steroids to estrogen, are used to treat endocrine-responsive breast cancer. As AIs lower estrogen levels, they increase bone tur...

Full description

Saved in:
Bibliographic Details
Published in:Endocrinology and metabolism (Seoul) 2015, 30(1), , pp.58-64
Main Authors: Kim, Wonjin, Chung, Yoonjung, Kim, Se Hwa, Park, Sehee, Bae, Jae Hyun, Kim, Gyuri, Lee, Su Jin, Kim, Jo Eun, Park, Byeong Woo, Lim, Sung Kil, Rhee, Yumie
Format: Article
Language:English
Subjects:
Aromatase inhibitors
Breast neoplasms
Original
Osteoporosis
Sclerostin
내과학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sclerostin is a secreted Wnt inhibitor produced almost exclusively by osteocytes, which inhibits bone formation. Aromatase inhibitors (AIs), which reduce the conversion of steroids to estrogen, are used to treat endocrine-responsive breast cancer. As AIs lower estrogen levels, they increase bone turnover and lower bone mass. We analyzed changes in serum sclerostin levels in Korean women with breast cancer who were treated with an AI. We included postmenopausal women with endocrine-responsive breast cancer (n=90; mean age, 57.7 years) treated with an AI, and compared them to healthy premenopausal women (n=36; mean age, 28.0 years). The subjects were randomly assigned to take either 5 mg alendronate with 0.5 μg calcitriol (n=46), or placebo (n=44) for 6 months. Postmenopausal women with breast cancer had significantly higher sclerostin levels compared to those in premenopausal women (27.8±13.6 pmol/L vs. 23.1±4.8 pmol/L, P
ISSN:2093-596X
2093-5978
DOI:10.3803/EnM.2015.30.1.58